Hypertriglyceridemia, Hyperlipidemias, High Cholesterol, High Triglycerides, Triglycerides
The study is a randomized, double-blind, placebo-controlled (corn oil), parallel group design that will enroll approximately 13,000 patients with hypertriglyceridemia and low HDL and high risk for CVD to be randomized 1:1 to either corn oil + statin or Epanova + statin, once daily, for approximately 3-5 years as determined when the number of MACE outcomes is reached.
5 Office Visits over a 7 month Period.
The purpose of this study is to find out if an investigational vaccine prevents severe diarrhea caused by a germ (bacterium) called Clostridium difficile (C diff). Vaccines help your body to make antibodies which help to fight against diseases (this is also called an immune response).
C diff is a significant cause of infectious diarrhea. Its severity can range from being mild to severe, and can lead to death. Most people who get C diff diarrhea are older and:
• Have hospital stays, or;
• See their doctor often, or;
• Live in a nursing home, or;
• Take antibiotics.
As one or more of these items may apply to you, you are being asked to take part in this study. To find out whether the vaccine prevents C diff diarrhea, we will closely monitor you for signs of infection for up to 3 years after you receive your last vaccine. We will also collect information on any side effects the C diff vaccine might cause and your general health.
In this study, you will receive 3 injections over a period of 6 months. You will receive the investigational C diff vaccine or a placebo. An investigational vaccine is one that is currently not approved for sale in this country. A placebo looks like the investigational vaccine, but does not have any active ingredients
13 Office Visits over a 16-week period.
The purpose of this study is to evaluate patiromer treatment with spironolactone in subjects with resistant hypertension and CKD. The study will evaluate whether using patiromer with spironolactone will allow more persistent use of spironolactone by preventing high blood potassium. It is anticipated that more persistent use of spironolactone will result in better blood pressure control.
Must be on 3 hypertension meds (one being a diuretic)
Must be diagnosed with Chronic Kidney Disease-Stage III or IV.
14 Office Visits over 3 to 5 years.
Must be at least 18 years of age, with Triglyceride levels between 180 and 500. Must be on a stable dose of a "statin". Cannot take fish oil during the study, as the study is on a new type of fish oil. Must have history of cardiovascular events/risks in records.
10 Office Visits over a 33-Week Period.
You may qualify if you match the following criteria:
• Aged 18 to 80 years old
• Diagnosed with moderate to severe Chronic Plaque Psoriasis (covers at least 25% of your body) for at least 6 months
• Symptoms stable for 2 months prior to first visit
• No biological treatments within 6 months prior to first visit
• No autoimmune diseases, coronary artery disease, heart failure or gastrointestinal disorders
You will receive all of the following at no cost:
• Investigational medication
• All study-related health care and lab work
• Monetary compensation for your time and travel (Up to $680)
This study is a Phase 2, randomized, placebo controlled, dose ranging study of piromelatine (5, 20, and 50 mg daily for 6 months) versus placebo to determine an effective dose based on efficacy (cognitive performance), safety and tolerability in patients with mild dementia due to AD
The purpose of this study is to learn about health care use, costs, and clinical outcomes over time for amyloid positive participants with early stages of AD in the United States. This study is for research purposes only, and is not intended to treat any medical condition. No study therapy(ies) for AD will be administered.
Chronic Pain, Opioids, Drug Abuse, Opiate Addiction, Lower Back Pain
The purpose of this study is to evaluate the effect on pain intensity (PI) of structured discontinuation of long-term opioid analgesic therapy compared to continuation of opioid therapy in Suboptimal and Optimal Responders to high-dose, long-term opioid analgesic therapy for chronic low back pain (CLBP).
This registry will be used to identify patients who have etiology diagnosed or suspected to be Alzheimer's disease and positive amyloid scans, and have indicated their interest in being contacted for an Eli Lilly and Company (Lilly) Alzheimer's Disease drug research trial.